Author: Sana Biotechnology, Inc

Posted Date:

May 12, 2026

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

Sana Biotechnology, Inc

May 12, 2026
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc

May 11, 2026
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Sana Biotechnology, Inc

May 5, 2026
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology, Inc

April 27, 2026
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451

Sana Biotechnology, Inc

April 13, 2026
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana Biotechnology, Inc

March 13, 2026
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology, Inc

March 3, 2026
Sana Biotechnology to Present at March 2026 Investor Conferences

Sana Biotechnology, Inc

February 23, 2026
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

Sana Biotechnology, Inc

February 17, 2026